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ABSTRACT
Objective: To conduct a cross-cultural adaptation of the Bath Ankylosing Spondylitis Functional Index (BASFI) into 
Brazilian-Portuguese language and to assess its measurement properties. Methods: The BASFI was translated by four 
rheumatologists and three English teachers. The translated questionnaire was applied to ankylosing spondylitis patients 
by trained observers, and self-administered in three moments: days 1, 2, and 14. The validity was assessed analyzing 
the association of BASFI and functional capacity measures (cervical rotation, intermalleolar distance, Schober’s test 
and occiput-to-wall distance). The internal consistence was tested by Cronbach’s α coeffi cient and the reliability by test-
retest (intraclass correlation coeffi cient – ICC). Results: A total of 60 patients with ankylosing spondylitis was included: 
85% male, mean age 47 ± 12 years, and mean disease duration 20 ± 11 years. The intra-observer test-retest (two-week 
interval) reliability showed a high ICC (0.999, 95% CI: 0.997–0.999) and a high internal consistency (Cronbach’s α 
coeffi cient: 0.86, CI 95%: 0.80–0.90). Considering the validity, the BASFI indices were correlated with cervical rota-
tion (0.53, P < 0.001) and with intermalleolar distance (0.50, P < 0.001). Conclusion: The BASFI Brazilian-Portuguese 
version is reliable and valid for assessment of patients with ankylosing spondylitis.
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INTRODUCTION
Ankylosing spondylitis (AS) is a chronic rheumatic disease 
with a worldwide prevalence of up to 0.9%.1 Men are more 
commonly affected than women, similar to other spondylo-
arthritis HLA-B27-positive related diseases.2 The sacroiliac 
joints are affected and, to a varying degree, the spinal column, 
while peripheral joints may be involved, specially in the lower 
limbs. Patients commonly experience pain, morning stiffness 
and disability, generally increasing with long standing disease.3 
There is no single “gold standard” management and prog-
nostic factors for AS because of its heterogeneous nature, 
long standing characteristic and, until recently, lack of ap-
propriate, validated outcome measures.4 As consequence, the 
optimal quantitative measures to monitor status and to assess 
long-term prognosis are often derived from patient self-report 
questionnaires. This has resulted in signifi cant increase in the 
availability of patient-assessed health instruments which aim to 
measure aspects of health from the perspective of the patient. 
These instruments usually contain multiple items or questions 
to refl ect the broad nature of health status, disease, or injury.5,6
In fact, an interesting systematic literature review 
(1988–2004) have been done to retrieve references re-
lated to the development and evaluation of multi-item 
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patient-assessed health instruments (12 AS-specific and 
three arthritis-specific). Among the instruments evaluated, 
both The Bath Ankylosing Spondylitis Functional Index 
(BASFI) and Dougados Functional Index (DFI) demon-
strated acceptable levels of reliability with good evidence 
for construct validity and similar levels of responsiveness 
following drug therapy evaluation. The BASFI is an AS 
specific functional index, worldwide accepted, has shown 
better content validity, and it is more responsive following 
physical therapy.7 
Recently, the Assessment in Ankylosing Spondylitis Group 
(ASAS) have recommended several domains for the evaluation 
of patients with AS in both clinical research and routine prac-
tice, which include the analysis of functional disability, spinal 
stiffness, and pain.8 In this regard, patient-assessed instruments 
with measurement properties to support their role in evaluation 
should be identifi ed to fulfi ll these domains.9
Therefore, with increasing numbers of multinational 
and multicultural research projects, the need to adapt 
health status measures for use in other than the source 
language has also grown rapidly. Because there was no 
Brazilian-Portuguese version of this instrument to assess 
AS functional ability, we decided to translate and cultur-
ally adapt the BASFI, based on its strong measurement 
properties, described in the literature. Thus, in order to 
develop a Brazilian-Portuguese version of the BASFI, the 
aim of the present study was to do a cross-cultural adaptation 
of the BASFI into Brazilian-Portuguese and to validate it 
in AS patients, following the international guidelines.10 
The BASFI satisfi es the criteria required for a functional 
index because it is quick and easy to complete, reliable, and 
sensitive to change across the whole spectrum of disease. 
The validity and reliability of the original BASFI English 
version, as well as other language’s versions, has been 
demonstrated.11–15 In addition, the BASFI questionnaire has 
been approved by OMERACT IV fi lter for use as functional 
index in spondyloarthritis.16
PATIENTS AND METHODS
Sixty patients were consecutively selected from the 
Rheumatology Division of the Universidade de São Paulo 
during a period of six months. The inclusions are based on 
the diagnosis of AS accordingly to the New York criteria.17 
All patients had to be able to answer the questionnaires and an 
informed consent was obtained from all participants. Patients 
who were attending any rehabilitation intervention/program 
were excluded.
BASFI
This self-assessment instrument was designed by a team of 
medical professionals and patients and consists of eight specifi c 
questions regarding physical function in AS and two questions 
refl ecting the patient’s ability to cope with everyday life.18 Each 
question is answered on a 10 cm horizontal Visual Analogue 
Scale, scoring from 0–10. The questionnaire is easily under-
stood and can be self-administered or applied by an interviewer. 
All results are the arithmetic sum of the answers, considering 
that 0 is no disability and 10 is the maximum disability. The 
BASFI satisfi es the criteria required for a functional index and 
it is brief and easy to be completed, reliable, and sensitive to 
change across the whole spectrum of disease.18
Translation process
The translation of the BASFI was done into three steps. First, 
four rheumatologists fl uent in English and one English teacher 
translated the original BASFI (English version) into Brazilian-
Portuguese (T1). Secondly, this version (T1) was back-translated 
into English by a second English teacher (blinded about the 
disease and from the objectives of the study) (BT1). Afterwards, 
a third English teacher translated the BT1 into Brazilian-
Portuguese (T2). Finally, the committee, composed by the 
rheumatologists and English teachers involved in the translation 
process, consensually defi ned the fi nal version (T12).
This study was approved by the Ethics Committee of the 
Hospital de Clínicas, Medical School, Universidade de São 
Paulo and the author of BASFI have formally allowed and 
authorized its translation into Brazilian-Portuguese language 
and to culturally adapt it.
BASFI application
On day 1 (D1) all patients who fulfi lled the inclusion criteria 
had their physical parameters taken by a trained physical 
therapist (PT). The measures evaluated were: cervical rota-
tion (CR) (goniometer), intermalleolar distance (IMD) (cm), 
Schober test (ST) and occiput-to-wall distance (OWD) (cm). 
Afterwards, all patients were interviewed by the fi rst observer 
(O1) to fi ll out the questionnaire (BASFI). All patients were 
interviewed by a second observer (O2) in the same day (D1), 
to assess the inter-observer test-retest reliability. On day 2 
(D2) all patients fi lled the BASFI at home (self-administered) 
and were instructed not to change their daily activities and 
to answer the questionnaires in the morning period. On the 
fourteenth day (D14) all patients were interviewed again by 
the same fi rst observer (O1) to fi ll the BASFI questionnaire 
and were blinded from their previous answers (D1).
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Statistical analysis
All data was given as measures of central tendency and 
dispersion. Reliability (intra-, inter-observer and observer X 
self-administered) were analyzed by the intraclass correla-
tion coeffi cient (ICC) and the internal consistency was tested 
by the Cronbach’s α coeffi cient. Multiple linear regressions 
were applied for evaluation of the construct validity between 
BASFI indices and physical measures (CR, IMD, ST, OWD). 
A P < 0.05 was considered statistically signifi cant.
RESULTS 
A total of 60 AS patients participated in the study. Eighty 
fi ve percent were men, mean age of 47 ± 12 years and mean 
disease duration of 20 ± 11 years. Educational level was 
divided according to years at school and more than a half 
of the patients studied less than fi ve years (56.7% < 5 years, 
21.7% from 5–9 years, 13.3% from 9–12 years and only 
8.3% > 12 years). 
Mean total score of BASFI obtained in this group was 
4.45 ± 2.43. For validity, the BASFI indices were correlated 
to CR (mean 29.3 ± 20.6 grade, 0.53, P < 0.001/exponential), 
IMD (mean 61.9 ± 25.3 cm, 0.50, P < 0.001/cubic). The BASFI 
indices were not signifi cantly correlated to the ST (mean 
2.9 ± 2.97 cm, 0.85, P = 0.51) and OWD (mean 8.2 ± 6.93 cm, 
0.22, P = 0.09).
Multiple regression was applied to assess the infl uence of 
the variables age, disease duration and education level in the 
BASFI indices. There was no statistical signifi cant infl uence 
of those variables in the BASFI indices (data not shown). 
The inter-observer reliability (ICC) was 0.95, 95% CI: 
0.91–0.97. In the observer X self-administered reliability 
(ICC) the result was 0.96, 95% CI: 0.93–0.96 while in the 
intra-observer reliability (ICC) the fi gure was 0.999, 95% CI: 
0.997–0.999. The internal consistency (Cronbach’s α) was 
0.86, 95% CI: 0.80–0.90. 
DISCUSSION 
At literature we have found some physical and cultural char-
acteristics in AS patients around the world. Much of results 
differ between countries. Our results suggest that the self-
administered Brazilian BASFI can be a useful alternative either 
in further studies or in clinical practice.
In our study, mean BASFI results were similar to a Spanish 
study (4.3 ± 2.4) and one from United Kingdom (5 ± 2.6).11,19 
The clinical characteristics of our patients and disease 
severity were similar. Our patients have longer disease than 
Spanish group (11 ± 7.8) and also the United Kingdom group 
(9.9 ± 9.8).
In contrast of two recent Turkish studies, our patients 
were older with more disease duration and worse BASFI 
results compared to their data.20,21 Furthermore, in our study 
the BASFI results had no correlation with age. This is in line 
with Turkish and Finnish studies. In the Finnish study only DFI 
showed correlation with age.13,15 However, the BASFI Chinese 
version showed weak correlations both with age and disease 
duration.22 In fact, it is possible that not only age but other 
variables combined result in disease severity and functional 
disability so that, as a consequence, a patient could be older 
but with less severe disease, while a younger patient could 
have more severe disease.
The reliability (ICC) of the present study was very good 
considering both the intra-observer (D1 X D14) and observer 
vs. self-administered approach (D1 X D2) (0.99 and 0.96, 
respectively). The inter-observer reliability (at the same day) 
also showed good results (0.95, 95% CI: 0.91–0.97). The 
same trend was found in one study whose BASFI test-retest 
Spearman’s rank correlation coeffi cient was 0.91 (P < 0.0001) 
for the global BASFI score.11 These results are also in line 
with another study that applied the BASFI (self-administered 
approach in D1 and D2) and their results showed also an 
excellent reliability (ICC = 0.99).15 In addition, the test-retest 
reliability of BASFI was good, with a high intraclass correla-
tion coeffi cient between the two time points (24 hours interval, 
ICC = 0.93).13 In opposite direction, a Mexican-Spanish version 
found worse results than the studies described above. There was 
an acceptable 24-hour test-retest (ICC = 0.68).14 The internal 
consistency (Cronbach’s α = 0.86) in the present study was 
similar to other international studies.7,11,22,23
Most cross-cultural studies showed good BASFI validity, 
comparing its indices with clinical measurements but with 
differences in correlation. In the literature two studies found 
that the BASFI showed a negative correlation with Schober’s 
test of −0.444,21,24 one of them with signifi cant correlation 
of −0.31.22 In the present study we found no statistically sig-
nifi cant correlation between the BASFI and the Schober’s test 
(0.85, P = 0.518). 
BASFI showed a positive correlation with OWD22,24 and no 
correlation in another21 (0.33, 0.535 respectively). We found 
no statistically signifi cant correlation between the BASFI with 
the OWD (0.22, P = 0.095). The selection bias could explain the 
lack of correlation between BASFI scores, the Schober’s test 
and OWD in our study. The majority of patients had long term 
disease duration and had no signifi cant physical limitation. 
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One study showed negative but weak correlation between 
the BASFI with the measurements of lumbar fl exion (r = −0.38, 
P = 0.001) and cervical rotation (r = 0.28, P = 0.013).13 We have 
found signifi cant correlations between BASFI with intermal-
leolar and cervical rotation.
Some studies describe patients’ diffi culty in fulfi lling the 
BASFI in a self-administered approach.25 That could be related 
to low socioeconomic level, because it was not observed in the 
developed countries.11,15 In Yanik’s study (Turkish patients), 
36% of the patients’ educational level was primary school and 
the questionnaire was well performed by the patients.13 In addi-
tion, Spanish patients also had no problems in understanding the 
questionnaire and spent a short time completing it.11 Although the 
BASFI is a self-administered questionnaire, we also applied it by 
face-to-face interviews, considering the low educational level of 
our sample (57% < 5 years of schooling) and our patients had no 
diffi culties in answer our Brazilian BASFI version in both formats. 
Our study had some weaknesses, including selection bias, 
because only patients attending our University tertiary facility 
were enrolled. The small sample size probably precluded the 
validity, considering the narrow physical functional disability 
of the patients. Therefore, further studies should also enroll 
patients from the community, considering different disease 
durations and disability levels. 
In conclusion, the Brazilian-Portuguese version of BASFI 
contributes to underscore the international fi ndings, such as 
feasibility, good reliability, and internal consistency.11,13,15 
Therefore, the Brazilian-Portuguese version of BASFI can be 
applied in AS patients. Further studies are necessary to cor-
roborate its measurement properties.
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